Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
2.
Rev Esp Quimioter ; 35(5): 475-481, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35796693

ABSTRACT

OBJECTIVE: Mortality of patients requiring Intensive Care Unit (ICU) admission for an invasive group A streptococcal (GAS) infection continues being high. In critically ill patients with bacteremic GAS infection we aimed at determining risk factors for mortality. METHODS: Retrospective multicentre study carried out in nine ICU in Southern Spain. All adult patients admitted to the participant ICUs from January 2014 to June 2019 with one positive blood culture for S. pyogenes were included in this study. Patient characteristics, infection-related variables, therapeutic interventions, failure of organs, and outcomes were registered. Risk factors independently associated with ICU and in-hospital mortalities were determined by multivariate regression analyses. RESULTS: Fifty-seven patients were included: median age was 63 (45-73) years, median SOFA score at admission was 11 (7-13). The most frequent source was skin and soft tissue infection (n=32) followed by unknown origin of bacteremia (n=12). In the multivariate analysis, age (OR 1.079; 95% CI 1.016-1.145), SOFA score (OR 2.129; 95% CI 1.339-3.383) were the risk factors for ICU mortality and the use of clindamycin was identified as a protective factor (OR 0.049; 95% CI 0.003-0.737). Age and SOFA were the independent factors associated with hospital mortality however the use of clindamycin showed a strong trend but without reaching statistical significance (OR 0.085; 95% CI 0.007-1.095). CONCLUSIONS: In this cohort of critically ill patients the use of intravenous immunoglobulin was not identified as a protective factor for ICU or hospital mortality treatment with clindamycin significantly reduced mortality after controlling for confounders.


Subject(s)
Bacteremia , Streptococcal Infections , Adult , Bacteremia/drug therapy , Clindamycin/therapeutic use , Critical Illness/therapy , Hospital Mortality , Humans , Immunoglobulins, Intravenous/therapeutic use , Intensive Care Units , Middle Aged , Retrospective Studies , Streptococcal Infections/drug therapy , Streptococcus pyogenes
3.
Med Intensiva (Engl Ed) ; 46(4): 179-191, 2022 04.
Article in English | MEDLINE | ID: mdl-35461665

ABSTRACT

OBJECTIVE: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators. DESIGN: Prospective descriptive multicenter cohort study. SETTING: 26 Intensive care units (ICU) from Andalusian region in Spain. PATIENTS OR PARTICIPANTS: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. INTERVENTIONS: None. VARIABLES: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied. RESULTS: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72.3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19.2%); 28 days mortality: 121/422 (28.7%); 6-week mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission >470U/L, Use of vasopressors, extrarenal depuration, %lymphocytes 72h post-ICU admission <6.5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor. CONCLUSION: Age, APACHE II, SOFA>value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor.


Subject(s)
COVID-19 , SARS-CoV-2 , Cohort Studies , Critical Illness , Female , Hospital Mortality , Humans , Infant , Lopinavir/therapeutic use , Male , Middle Aged , Prospective Studies , Ritonavir/therapeutic use
4.
Med. intensiva (Madr., Ed. impr.) ; 46(4): 179-191, abr. 2022. tab
Article in English | IBECS | ID: ibc-204248

ABSTRACT

Objective: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators. Design: Prospective descriptive multicenter cohort study. Setting: 26 Intensive care units (ICU) from Andalusian region in Spain. Patients or participants: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. Interventions: None. Variables: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied. Results: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72.3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19.2%); 28 days mortality: 121/422 (28.7%); 6-week mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission >470U/L, Use of vasopressors, extrarenal depuration, %lymphocytes 72h post-ICU admission <6.5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor. Conclusion: Age, APACHE II, SOFA>value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor (AU)


Objetivo: Identificar los factores de riesgo asociados con la mortalidad a las seis semanas. Diseño: Estudio prospectivo multicéntrico. Ámbito: Se incluyeron a 26 pacientes de la Unidad de Cuidados Intensivos (UCI) de Andalucía. Pacientes o participantes: Pacientes ingresados en UCI por neumonía grave por SARS-CoV-2 del 8 de marzo al 30 de mayo de 2020. Intervenciones: Ninguna. Variables de interés principales: Características demográficas, clínicas y escalas de gravedad. Se analizaron tratamientos de soporte, fármacos y la mortalidad. Resultados: Se incluyeron 495 pacientes, 73 fueron excluidos por incompletos y 422 pacientes se incorporaron en el análisis final. La mediana de edad fue de 63 años, 305 (72,3%) eran hombres. La mortalidad en la UCI fue: 144/422 34%; mortalidad a los 14 días: 81/422 (19,2%); mortalidad a los 28 días: 121/422 (28,7%); mortalidad a las seis semanas 152/422 36,5%. Los factores asociados con la mortalidad a los 42 días fueron la edad, APACHE II, SOFA > 6 y LDH al ingreso > 470 U/L, uso de vasopresores, necesidad de técnicas de reemplazo de la función renal, porcentaje de linfocitos a las 72 horas del ingreso en UCI < 6,5%, y trombocitopenia, mientras que el uso de lopinavir/ritonavir fue identificado como un factor protector. Conclusiones: La edad, gravedad y fracaso orgánico junto con la necesidad de terapias de soporte fueron identificadas como factores predictores de mortalidad a las seis semanas. La administración de corticoesteroides a dosis altas no mostró beneficios en la mortalidad, al igual que el tratamiento con tocilizumab, lopinavir/ritonavir se identificaron como un factor protector (AU)


Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Coronavirus Infections/mortality , Pneumonia, Viral/mortality , Pandemics , Hospital Mortality , Prospective Studies , Cohort Studies , Critical Illness , Risk Factors , Severity of Illness Index
5.
Med. intensiva (Madr., Ed. impr.) ; 45(5): 271-279, Junio - Julio 2021. graf, tab
Article in Spanish | IBECS | ID: ibc-222309

ABSTRACT

Objetivo Conocer el destino de los trabajos rechazados en Medicina Intensiva (MI) en el período del 2015 al 2017 con seguimiento hasta el 2019. Diseño Estudio retrospectivo observacional. Ámbito Publicaciones en revistas biomédicas. Participantes Manuscritos rechazados en la revista Medicina Intensiva. Intervenciones Ninguna Variables de interés Tiempo de publicación, factor de impacto (FI), citas generadas y variables asociadas con la publicación. Resultados De 344 originales y 263 cartas científicas, se rechazaron 420 (69,2%). Se publicaron después 205 (48,8%) y 66 de ellos generaron 180 citas. El FI de las revistas fue menor en 173 casos (84,4%). En 21, el número de citas válidas para FI fue mayor que el FI de MI. El origen del manuscrito odds ratio (OR) 2,11 (IC 95% 1,29 a 3,46), la mujer como autora OR 1,58 (IC 95% 1,03 a 2,44), que estuviera en lengua inglesa OR 2,38 (IC 95% 1,41 a 4,0) y que el artículo hubiera pasado a revisores OR 1,71 (IC 95% 1,10 a 2,66) se asociaron con mayor tasa de publicación en revistas indexadas en PubMed. Conclusiones Los artículos rechazados en MI tienen una tasa media de publicación en otras revistas, principalmente con menos FI y generando menor número de citas que el FI de MI. (AU)


Objective To know the fate of the rejected manuscripts in Medicina Intensiva journal (MI) from 2015 to 2017 with surveillance until 2019. Design Retrospective observational study. Setting Biomedical journals publication. Participants Rejected manuscripts in MI journal. Interventions None. Main variables of interest Time of publication, impact factor (IF), generated citations and variables associated to publication. Results The 69% (420) of analyzed articles (344 originals and 263 scientific letters) were rejected, and 205 (48.8%) were subsequently published, with 180 citations of 66 articles. Journal IF was lower in 173 (84.4%) articles. The number of FI-valid citations was higher than the FI of MI in 21 articles. Origin of manuscript OR 2,11 (IC 95% 1.29 – 3.46), female author OR 1.58 (IC 95% 1.03-2.44), english language OR 2,38 (IC 95% 1.41-4.0) and reviewed papers OR 1.71 (IC 95% 1.10-2.66) were associated to publication in PubMed database. Conclusions The rejected articles in MI have a mean publication rate in other journals. Most of these articles are published in journals with less IF and fewer citations than the IF of MI. (AU)


Subject(s)
Humans , Impact Factor , Peer Review , Bibliometrics , Gender Identity
6.
Med Intensiva (Engl Ed) ; 45(5): 271-279, 2021.
Article in English | MEDLINE | ID: mdl-34059217

ABSTRACT

OBJECTIVE: To know the fate of the rejected manuscripts in Medicina Intensiva journal (MI) from 2015 to 2017 with surveillance until 2019. DESIGN: Retrospective observational study. SETTING: Biomedical journals publication. PARTICIPANTS: Rejected manuscripts in MI journal. INTERVENTIONS: None. MAIN VARIABLES OF INTEREST: Time of publication, impact factor (IF), generated citations and variables associated to publication. RESULTS: The 69% (420) of analyzed articles (344 originals and 263 scientific letters) were rejected, and 205 (48.8%) were subsequently published, with 180 citations of 66 articles. Journal IF was lower in 173 (84.4%) articles. The number of FI-valid citations was higher than the FI of MI in 21 articles. Origin of manuscript OR 2,11 (IC 95% 1.29-3.46), female author OR 1.58 (IC 95% 1.03-2.44), english language OR 2,38 (IC 95% 1.41-4.0) and reviewed papers OR 1.71 (IC 95% 1.10-2.66) were associated to publication in PubMed database. CONCLUSIONS: The rejected articles in MI have a mean publication rate in other journals. Most of these articles are published in journals with less IF and fewer citations than the IF of MI.


Subject(s)
Peer Review, Research , Publishing , Female , Humans , Journal Impact Factor , Language , PubMed
7.
Article in English, Spanish | MEDLINE | ID: mdl-33812670

ABSTRACT

OBJECTIVE: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators. DESIGN: Prospective descriptive multicenter cohort study. SETTING: 26 Intensive care units (ICU) from Andalusian region in Spain. PATIENTS OR PARTICIPANTS: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. INTERVENTIONS: None. VARIABLES: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied. RESULTS: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72.3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19.2%); 28 days mortality: 121/422 (28.7%); 6-week mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission >470U/L, Use of vasopressors, extrarenal depuration, %lymphocytes 72h post-ICU admission <6.5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor. CONCLUSION: Age, APACHE II, SOFA>value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor.

8.
J Healthc Qual Res ; 36(4): 217-224, 2021.
Article in Spanish | MEDLINE | ID: mdl-33863683

ABSTRACT

BACKGROUND AND OBJECTIVE: Pediatric patient care implies a duplication of user, the children who receive assistance and their parents. OBJECTIVE: to evaluate the perception and compared experience between children seen in pediatric observation and their parents. PATIENTS AND METHODS: Cross-sectional study using a survey prior to discharge, to children aged 4-13 years admitted between April 2017 and November 2018 and their parents. A random sample of 125 child-parent pairs was taken. Both groups were compared with the Chi-square test and the child-father agreement with the Kappa index (KI), using SPSS v.25. RESULTS: Overall satisfaction was 99.2% in children and 100% in adults, with no significant differences between the two (p=0.314). There were also no significant differences between children and parents in the best valued aspects: staff interest (100% and 100%; p=not calculable); treatment of staff (100% and 99.2%; p=0.318); space (99.2% and 99.2%; p=1); information (98.4% and 100%; p=0.993); time with relatives (98.4% and 98.4%; p=0.993); cleaning (98.4% and 97.6%; p=0.651). The worst valued aspects in children: food (83.2% and 93.2%; p=0.016) and entertainment (89.5% and 94.2%; p=0.179); in adults: comfort (96.8% and 90.2%; p=0.036). There was moderate child-parent concordance in speed of attention (IK 0.561; p<0.001), time with relatives (0.492; p<0.001) and entertainment (0.489; p<0.001). In four questions, the IK could not be calculated because there were no dissatisfied adults and / or children. CONCLUSIONS: The global satisfaction of children and adults was high and consistent in most items. Parent surveys reflect the views of children.


Subject(s)
Parents , Adult , Child , Cross-Sectional Studies , Humans , Surveys and Questionnaires
10.
Med Intensiva (Engl Ed) ; 45(5): 271-279, 2021.
Article in English, Spanish | MEDLINE | ID: mdl-33509644

ABSTRACT

OBJECTIVE: To know the fate of the rejected manuscripts in Medicina Intensiva journal (MI) from 2015 to 2017 with surveillance until 2019. DESIGN: Retrospective observational study. SETTING: Biomedical journals publication. PARTICIPANTS: Rejected manuscripts in MI journal. INTERVENTIONS: None. MAIN VARIABLES OF INTEREST: Time of publication, impact factor (IF), generated citations and variables associated to publication. RESULTS: The 69% (420) of analyzed articles (344 originals and 263 scientific letters) were rejected, and 205 (48.8%) were subsequently published, with 180 citations of 66 articles. Journal IF was lower in 173 (84.4%) articles. The number of FI-valid citations was higher than the FI of MI in 21 articles. Origin of manuscript OR 2,11 (IC 95% 1.29 - 3.46), female author OR 1.58 (IC 95% 1.03-2.44), english language OR 2,38 (IC 95% 1.41-4.0) and reviewed papers OR 1.71 (IC 95% 1.10-2.66) were associated to publication in PubMed database. CONCLUSIONS: The rejected articles in MI have a mean publication rate in other journals. Most of these articles are published in journals with less IF and fewer citations than the IF of MI.

16.
Med Intensiva (Engl Ed) ; 43(2): 121-123, 2019 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-30678997

ABSTRACT

The series of updates on methodology for research in critically ill patients has addressed the difficulties caused by the characteristics of patients of this kind, bioethics, the interpretation of results, and methodological error. New statistical methods for causality research, meta-analysis and big data analysis have also been described. The last update refers to the horizon for new research in the field of critical care. We close the series with the hope of having provided a global vision of the statistical methods oriented toward the future, with the aim of promoting statistical culture. In parallel, we have analyzed the evolution in complexity of the methodological analysis in the journal.


Subject(s)
Critical Care/methods , Periodicals as Topic , Publishing/statistics & numerical data , Humans , Spain
17.
Med Intensiva (Engl Ed) ; 42(6): 370-379, 2018.
Article in English, Spanish | MEDLINE | ID: mdl-29477785

ABSTRACT

The appropriate interpretation of the statistical results is crucial to understand the advances in medical science. The statistical tools allow us to transform the uncertainty and apparent chaos in nature to measurable parameters which are applicable to our clinical practice. The importance of understanding the meaning and actual extent of these instruments is essential for researchers, the funders of research and for professionals who require a permanent update based on good evidence and supports to decision making. Various aspects of the designs, results and statistical analysis are reviewed, trying to facilitate his comprehension from the basics to what is most common but no better understood, and bringing a constructive, non-exhaustive but realistic look.


Subject(s)
Data Interpretation, Statistical
18.
Med Intensiva (Engl Ed) ; 42(3): 180-183, 2018 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-29426703

ABSTRACT

Research in the critically ill is complex by the heterogeneity of patients, the difficulties to achieve representative sample sizes and the number of variables simultaneously involved. However, the quantity and quality of records is high as well as the relevance of the variables used, such as survival. The methodological tools have evolved to offering new perspectives and analysis models that allow extracting relevant information from the data that accompanies the critically ill patient. The need for training in methodology and interpretation of results is an important challenge for the intensivists who wish to be updated on the research developments and clinical advances in Intensive Medicine.


Subject(s)
Bibliometrics , Critical Care , Medicine , Periodicals as Topic/statistics & numerical data , Research Design , Big Data , Clinical Trials as Topic , Critical Care/methods , Critical Illness , Data Interpretation, Statistical , Data Mining , Hospital Records , Humans , Multicenter Studies as Topic , Peer Review
SELECTION OF CITATIONS
SEARCH DETAIL
...